EMA Reflection Paper on risk based Quality Management in Clinical Trials
The European Medicines Agency EMA has recently released a draft reflection paper on risk based quality management in clinical trials.
The purpose of this reflection paper is to facilitate the development of a more systematic, prioritised, risk-based approach to quality management of clinical trials, to support the principles of Good Clinical Practice and to complement existing quality practices, requirements and standards.
Please also see the reflection paper available for consultation for further details.
Comments related to this reflection paper should be provided using this template. The completed comments form should be sent to GCP@ema.europa.eu.
Please note that the deadline for comments for this reflection paper is 15 February 2012.
Related GMP News
11.12.2025Insurance Review in Phase 1 Clinical Trials
11.12.2025EMA Publishes Comments on ICH E21
27.11.2025Final ICH M14 Guideline on the Use of RWD for Safety Assessment
25.11.2025Clinical Trials: BMG publishes Standard Contractual Clauses Ordinance
04.11.2025UK Clinical Trials Regulations: Six-Month Countdown
04.11.2025Clinical Trials - Update on the CTIS